Inventor · disambiguated record
Ravi V. J. Chari
Also filed as: CHARI RAVI · CHARI RAVI S · CHARI RAVI V · CHARI RAVI V J
93 granted patents·37 pending applications·5,976 citations·filing 1990–2025
99Inventor score
Top patents by PatentIndex Score
130 records- 0199US8809320B2Benzodiazepine derivativesLI WEI·Filed 2013·Granted Aug 19, 2014·56 cites·22 claims
- 0299US8802667B2Benzodiazepine derivativesLI WEI·Filed 2013·Granted Aug 12, 2014·55 cites·20 claims
- 0399US7851432B2Cytotoxic agents comprising new maytansinoidsIMMUNOGEN INC·Filed 2007·Granted Dec 14, 2010·54 cites·33 claims
- 0499US7601354B2Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agentsIMMUNOGEN INC·Filed 2006·Granted Oct 13, 2009·161 cites·17 claims
- 0599US7368565B2Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agentsIMMUNOGEN INC·Filed 2002·Granted May 6, 2008·239 cites·17 claims
- 0699US7303749B1Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agentsIMMUNOGEN INC·Filed 2000·Granted Dec 4, 2007·226 cites·16 claims
- 0799US7276497B2Cytotoxic agents comprising new maytansinoidsIMMUNOGEN INC·Filed 2004·Granted Oct 2, 2007·402 cites·31 claims
- 0899US7276499B2Cytotoxic agents comprising taxanes and their therapeutic useIMMUNOGEN INC·Filed 2006·Granted Oct 2, 2007·58 cites·21 claims
- 0999US6716821B2Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the sameIMMUNOGEN INC·Filed 2001·Granted Apr 6, 2004·359 cites·92 claims
- 1099US6630579B2Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic useIMMUNOGEN INC·Filed 2000·Granted Oct 7, 2003·547 cites·16 claims
- 1199US6596757B1Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic useIMMUNOGEN INC·Filed 2002·Granted Jul 22, 2003·165 cites·48 claims
- 1299US6436931B1Cytotoxic agents comprising taxanes and their therapeutic useIMMUNOGEN INC·Filed 2002·Granted Aug 20, 2002·184 cites·24 claims
- 1399US6340701B1Cytotoxic agents comprising taxanes and their therapeutic useIMMUNOGEN INC·Filed 2000·Granted Jan 22, 2002·271 cites·24 claims
- 1499US5585499ACyclopropylbenzindole-containing cytotoxic drugsIMMUNOGEN INC·Filed 1995·Granted Dec 17, 1996·541 cites·8 claims
- 1599US5475092ACell binding agent conjugates of analogues and derivatives of CC-1065IMMUNOGEN INC·Filed 1994·Granted Dec 12, 1995·668 cites·8 claims
- 1698US9434748B2Cytotoxic benzodiazepine derivativesIMMUNOGEN INC·Filed 2015·Granted Sep 6, 2016·15 cites·25 claims
- 1798US8889669B2Cytotoxic benzodiazepine derivativesLI WEI·Filed 2013·Granted Nov 18, 2014·32 cites·40 claims
- 1898US8765740B2Cytotoxic benzodiazepine derivativesLI WEI·Filed 2012·Granted Jul 1, 2014·59 cites·56 claims
- 1998US8088387B2Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugatesSTEEVES RITA M·Filed 2004·Granted Jan 3, 2012·146 cites·143 claims
- 2098US7989598B2Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugatesIMMUNOGEN INC·Filed 2007·Granted Aug 2, 2011·46 cites·53 claims
- 2198US7473796B2Cytotoxic agents comprising new maytansinoidsIMMUNOGEN INC·Filed 2007·Granted Jan 6, 2009·55 cites·13 claims
- 2298US7388026B2Prodrugs of CC-1065 analogsIMMUNOGEN INC·Filed 2005·Granted Jun 17, 2008·68 cites·6 claims
- 2398US6756397B2Prodrugs of CC-1065 analogsIMMUNOGEN INC·Filed 2002·Granted Jun 29, 2004·144 cites·5 claims
- 2498US6586618B1CC-1065 analog synthesisIMMUNOGEN INC·Filed 2002·Granted Jul 1, 2003·125 cites·2 claims
- 2597US9169272B2Cytotoxic benzodiazepine derivativesIMMUNOGEN INC·Filed 2014·Granted Oct 27, 2015·19 cites·16 claims
- 2697US8426402B2Benzodiazepine derivativesLI WEI·Filed 2010·Granted Apr 23, 2013·69 cites·23 claims
- 2797US8236319B2Cross-linkers and their usesCHARI RAVI V J·Filed 2009·Granted Aug 7, 2012·60 cites·15 claims
- 2897US8198417B2Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugatesSTEEVES RITA M·Filed 2007·Granted Jun 12, 2012·59 cites·65 claims
- 2997US7655661B2Prodrugs of CC-1065 analogsIMMUNOGEN INC·Filed 2008·Granted Feb 2, 2010·35 cites·7 claims
- 3097US7655660B2Prodrugs of CC-1065 analogsIMMUNOGEN INC·Filed 2007·Granted Feb 2, 2010·39 cites·7 claims
- 3197US7049316B2Prodrugs of CC-1065 analogsIMMUNOGEN INC·Filed 2003·Granted May 23, 2006·77 cites·9 claims
- 3296US10844135B2Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making saidIMMUNOGEN INC·Filed 2017·Granted Nov 24, 2020·7 cites·35 claims
- 3396US10208127B2Benzodiazepine derivativesIMMUNOGEN INC·Filed 2018·Granted Feb 19, 2019·6 cites·6 claims
- 3496US10179818B2Cytotoxic benzodiazepine derivativesIMMUNOGEN INC·Filed 2017·Granted Jan 15, 2019·6 cites·24 claims
- 3596US9840564B2Cytotoxic benzodiazepine derivativesIMMUNOGEN INC·Filed 2016·Granted Dec 12, 2017·7 cites·3 claims
- 3696US9534000B2Cytotoxic benzodiazepine derivatives and methods of preparationCHARI RAVI V J·Filed 2012·Granted Jan 3, 2017·15 cites·28 claims
- 3795US7906545B2Prodrugs of CC-1065 analogsIMMUNOGEN INC·Filed 2009·Granted Mar 15, 2011·20 cites·8 claims
- 3895US7217819B2Cytotoxic agents comprising taxanes and their therapeutic useIMMUNOGEN INC·Filed 2005·Granted May 15, 2007·22 cites·6 claims
- 3994US9771432B2Conjugation methodsIMMUNOGEN INC·Filed 2016·Granted Sep 26, 2017·12 cites·22 claims
- 4094US9265841B2Benzodiazepine derivativesIMMUNOGEN INC·Filed 2014·Granted Feb 23, 2016·7 cites·12 claims
- 4194US9061995B2Cross-linkers and their usesIMMUNOGEN INC·Filed 2013·Granted Jun 23, 2015·17 cites·33 claims
- 4294US8685920B2Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugatesCHARI RAVI V J·Filed 2011·Granted Apr 1, 2014·16 cites·37 claims
- 4394US8624003B2Methods for preparation of antibody-maytansinoid conjugatesKELLOGG BRENDA A·Filed 2010·Granted Jan 7, 2014·42 cites·13 claims
- 4494US8613930B2Cross-linkers and their usesCHARI RAVI V J·Filed 2012·Granted Dec 24, 2013·17 cites·26 claims
- 4594US8435528B2Cytotoxic agents comprising new maytansinoidsCHARI RAVI V J·Filed 2007·Granted May 7, 2013·20 cites·30 claims
- 4694US8163736B2Cytotoxic agents comprising new tomaymycin derivativesGAUZY LAURENCE·Filed 2008·Granted Apr 24, 2012·151 cites·24 claims
- 4794US7585857B2Cytotoxic agents comprising taxanes and their therapeutic useIMMUNOGEN INC·Filed 2007·Granted Sep 8, 2009·15 cites·25 claims
- 4894US7329760B2CC-1065 analog synthesisIMMUNOGEN INC·Filed 2002·Granted Feb 12, 2008·31 cites·7 claims
- 4994US6372738B2Cytotoxic agents comprising taxanes and their therapeutic useIMMUNOGEN INC·Filed 2001·Granted Apr 16, 2002·179 cites·28 claims
- 5093US10570212B2Cytotoxic benzodiazepine derivativesIMMUNOGEN INC·Filed 2018·Granted Feb 25, 2020·3 cites·14 claims
Showing the top 50 of 130 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Ravi V. J. Chari files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →